Echo Therapeutics Announces Management Changes

                Echo Therapeutics Announces Management Changes

Robert Doman to Assume Role of Executive Chairman and Interim Chief Executive

PR Newswire

PHILADELPHIA, Aug. 26, 2013

PHILADELPHIA, Aug. 26, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its non-invasive Symphony^® CGM System as a
needle-free, wireless continuous glucose monitoring system, today announced
thatits Chief Executive Officer, President and Chairman of the Board, Dr.
Patrick Mooney, is taking an immediate leave of absence. Robert Doman, a
member of Echo's Board of Directors, will serve as Executive Chairman and
Interim Chief Executive Officer.

Mr. Doman has over 30 years of executive level, international and domestic
management, business development, sales and marketing, product development and
strategic planning experience with specific concentrations in medical devices
and pharmaceuticals. Most recently, Mr. Doman served as President and Chief
Executive Officer of publicly-traded DUSA Pharmaceuticals, Inc., which was
successfully sold to Sun Pharmaceuticals in a $230 million transaction in

Effective immediately, William Grieco, Chairman of the Company's Nominating
and Corporate Governance Committee and a member of Echo's Board since February
2011, has been appointed Lead Independent Director of the Board.

"Echo's business operations will continue as usual in Dr. Mooney's absence,"
said Mr. Doman. "We remain focused on completing our ongoing clinical studies
and filing the Symphony CGM System technical file for CE Marking in the near

The Board of Directors will be engaging an executive search firm to assist it
in identifying a new CEO. Mr. Grieco commented, "We're extremely fortunate to
have Bob serving as Executive Chairman and Interim CEO at this critically
important juncture for the Company."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system for use initially
in the critical care setting. Significant opportunity also exists for
Symphony to be used in the hospital beyond the critical care setting, as well
as in patients with diabetes in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
statements regarding the CEO's leave of absence and company performance. These
and other risks and uncertainties are identified and described in more detail
in Echo's filings with the Securities and Exchange Commission, including,
without limitation, its Annual Report on Form 10-K for the year ended December
31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Echo undertakes no obligation to publicly update or revise any
forward-looking statements.

For More Information:

Seth Lewis
Senior Vice President
The Trout Group, LLC
+1 646 378 2952

Connect With Us:
- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.

Press spacebar to pause and continue. Press esc to stop.